Common Stock, par value $0.01 per share
- Symbol
- MDRX
- Exchange
- NONE
- Classification
- COMMON
Current Report · Items 7.01, 9.01 · 8-K
VERADIGM INC
MDRXOTCEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. As previously announced, the Company will present at the 2026 Jefferies Healthcare Services and Technology Conference in Nashville, Tennessee on September 15, 2026 and will participate in the Deutsche Bank 2026 Healthcare Summit in New York, New York on September 16, 2026. A copy of the Company’s presentation is furnished as Exhibit 99.1.…
Company context
Veradigm has a proven history of delivering clinical and revenue cycle solutions that help independent practices improve outcomes and financial performance. Our AI-forward data and technology also help over 20,000 provider practices connect with health plans and biopharma to eliminate inefficiencies, close care gaps, and create a more affordable health system. © 2026 Veradigm LLC and/or its affiliates. All rights reserved. Cited marks are the property of Veradigm LLC and/or its affiliates. All other product or Company names are the property of their respective holders, all rights reserved.
Current securities
Historical securities (1)
Registered securities in this filing
VERADIGM INC. · 8-K · Filed 2026-09-15
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
As previously announced, the Company will present at the 2026 Jefferies Healthcare Services and Technology Conference in Nashville, Tennessee on September 15, 2026 and will participate in the Deutsche Bank 2026 Healthcare Summit in New York, New York on September 16, 2026. A copy of the Company’s presentation is furnished as Exhibit 99.1. The Company intends to use this presentation at other investor conferences.
The information furnished pursuant to this Item shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Filed exhibits (1)
EX-99.1 2 mdrx-ex99_1.htm EX-99.1 Investor Deck September 2026 VDMT-2697-AUG-2026 Exhibit 99.1 Disclaimer and Forward-Looking Statement Information This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding the Company’s preliminary estimated unaudited 2025 financial information, the Company's anticipated revenue growth and future financial performance, the Company's business and growth strategies, including its "reset, recover, reignite" strategy, the Company's product portfolio optimization and anticipated product roadmap, and the Company’s anticipated SEC filings and relisting on a national securities exchange. These forward-looking statements are based on the current beliefs and expectations of the Company’s management with respect to future events, only speak as of the date that they are made, and are subject to significant risks and uncertainties. Such statements can be identified by the use of words such as “future,” “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “will,” “would,” “could,” “continue,” “can,” “may,”…
Open exhibit ↗